Neil Nagovski, MD
Hematology & Oncology · Miami, FLNPI 1588635668
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $400,023 of the $529,731 with a category attached, or 75.5%. 58 manufacturers reported payments, led by Sanofi at 32.4% of the total. Reporting peaked in 2024 at $126,624 and has fallen 98.9% since, to $1,455 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 772 payments — averaging $686.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$171K
- E.r. Squibb & Sons, L.L.C.$73K
- GSK$70K
- Bristol Myers Squibb$67K
- Incyte Corporation$49K
- Novartis$38K
- plus $62K from 52 others
Across 8 payments — averaging $1393.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
- Sanofi US Services Inc.$3K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$640
What the payments were for
- Consulting fees$76,00914%
- Speaking & faculty fees$400,02376%
- Travel & lodging$35,9447%
- Food & beverage$17,6933%
- Education$620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$529,731 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 25 | $362,520 |
| CalquenceAcalabrutinib Maleate | 18 | $270,697 |
| RevlimidLenalidomide | 16 | $270,396 |
| JakafiRuxolitinib Phosphate | 16 | $270,305 |
| TasignaNilotinib Hcl | 12 | $240,022 |
| InqoviDecitabine/Cedazuridine | 13 | $106,913 |
| EliquisApixaban | 126 | $96,029 |
| Abiraterone Acetate | 21 | $37,751 |
| Ondansetron OdtOndansetron | 66 | $1,233 |
| Anastrozole | 44 | $714 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $682 |
| Hydroxyurea | 26 | $675 |
| Acyclovir | 61 | $619 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $404 |
| Pantoprazole Sodium | 36 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $29,383 | $270,69718 claims |
| Bristol Myers SquibbRevlimid | $66,916 | $270,39616 claims |
| Incyte CorporationJakafi | $49,074 | $270,30516 claims |
| NovartisTasigna | $38,113 | $240,02212 claims |
| Taiho Oncology, Inc.Inqovi | $3,286 | $106,91313 claims |
| PfizerEliquis | $1,374 | $96,029126 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $172 | $61961 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
- Gerald SoffMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.